NRX Pharmaceuticals Faces Agreement Termination, Eyes Accelerated Approval

NRX Pharmaceuticals (NRXP) has provided an announcement.

NRx Pharmaceuticals, Inc. has received an immediate termination notice from Alvogen regarding their joint development and marketing agreement for NRX-101, a breakthrough therapy for suicidal bipolar depression and chronic pain. While Alvogen has withdrawn due to the projected need for extensive clinical trials, NRx Pharmaceuticals believes recent trial findings support a viable application for Accelerated Drug Approval, targeting an estimated $3.7 billion market. The company plans to pursue this without a large commercial partner and is also finalizing a New Drug Approval for NRX-100.

For an in-depth examination of NRXP stock, go to TipRanks’ Stock Analysis page.